RVU — Ryvu Therapeutics SA Share News
0.000.00%
Last trade - 00:00- PLN417.09m
- PLN434.44m
- PLN62.25m
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys
Brief: Ryvu Therapeutics Signs Annex To Start Phase II Clinical Trial
Brief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project
Brief: Ryvu Therapeutics Says 'PERO' Project Recommended For Funding By National Centre For Research And Development
Brief: Ryvu Therapeutics Q3 Net Loss At 24.7 Million Zlotys
Brief: Ryvu Therapeutics Q2 Net Loss At 33.7 Million Zlotys
Brief: Ryvu Therapeutics Says RVU120 To Be Tested In Phase I Study Run By IPCZD
Brief: Ryvu Therapeutics Signs Deal To Support Clinical Trials For BioNTech’s Investigational Cancer Immunotherapies In Poland
Brief: Ryvu Therapeutics Q1 Net Loss At 25.3 Mln Zlotys
Brief: Ryvu Therapeutics Signs Grant Deal With Medical Research Agency
Brief: Ryvu Therapeutics Withdraws From Grant Agreement To Identify PRMT5 Inhibitor Markers
Brief: Ryvu Therapeutics FY Net Loss At 111.4 Mln Zlotys